This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Objective: To determine the role of the protective antibodies in killing and eliminating the infected cells. Also, to determine whether the protection against SHIV infection is better if one of these functions of antibodies -- either killing or eliminating infected cells -- is enhanced. (This project includes two main experiments.) In the current studies we use the recombinant Simian Human Immunodeficiency Virus (SHIV) infected-Rhesus macaque model to understand the role of two different functions of the protective antibodies against HIV infection in humans. For the first objective, we will treat two groups of animals with two different, but closely related antibodies that were genetically engineered to perform either the killing or the eliminating function well. We will compare the control of viremia in these two groups of animals and between three other groups of animals. One of the latter three groups of animals will not be treated with any antibody, the other group will be treated with an antibody that has both functions, and the third group will be treated with an antibody that has protective activity, but lacks killing activity and does not facilitate the eliminating of the infected cells either. For the second objective, we will treat two groups of animals with two different, but closely related antibodies that were genetically engineered to perform just one of these two functions at an enhanced level. We will compare the control of viremia in the two groups of animals and between groups of animals that will not be treated with any antibody, or will be treated with an antibody that has both functions at a normal level. PROGRESS: We have performed two pilot experiments. In the first pilot experiment, we titrated the new SHIV162P3 virus stock in vivo to determine the challenge dose that we will use in the main experiments. In the second pilot experiment, we determined the secretion kinetics of antibody NFb12 from the blood into the vaginal lumen. NFb12 antibody is a variant of the broadly neutralizing HIV antibody b12. Its Fc domain has been modified to enhance ADCC and phagocytosis. We have started the second experiment to determine the neutralization capabilities of antibody NFb12. We use a low concentration (1 mg/kg) of infused NFb12 against repeated low dose SHIV162P3 challenges. This research used Animal Services, CPI, and Virology &Immunology Services. PUBLICATIONS: None.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Primate Research Center Grants (P51)
Project #
5P51RR000167-50
Application #
8358236
Study Section
Special Emphasis Panel (ZRR1-CM-8 (01))
Project Start
2011-05-01
Project End
2012-04-30
Budget Start
2011-05-01
Budget End
2012-04-30
Support Year
50
Fiscal Year
2011
Total Cost
$238,342
Indirect Cost
Name
University of Wisconsin Madison
Department
Type
Other Domestic Higher Education
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Kang, HyunJun; Mesquitta, Walatta-Tseyon; Jung, Ho Sun et al. (2018) GATA2 Is Dispensable for Specification of Hemogenic Endothelium but Promotes Endothelial-to-Hematopoietic Transition. Stem Cell Reports 11:197-211
Rhoads, Timothy W; Burhans, Maggie S; Chen, Vincent B et al. (2018) Caloric Restriction Engages Hepatic RNA Processing Mechanisms in Rhesus Monkeys. Cell Metab 27:677-688.e5
Ellis-Connell, Amy L; Balgeman, Alexis J; Zarbock, Katie R et al. (2018) ALT-803 Transiently Reduces Simian Immunodeficiency Virus Replication in the Absence of Antiretroviral Treatment. J Virol 92:
Park, Mi Ae; Jung, Ho Sun; Slukvin, Igor (2018) Genetic Engineering of Human Pluripotent Stem Cells Using PiggyBac Transposon System. Curr Protoc Stem Cell Biol 47:e63
Ellis, Amy; Balgeman, Alexis; Rodgers, Mark et al. (2017) Characterization of T Cells Specific for CFP-10 and ESAT-6 in Mycobacterium tuberculosis-Infected Mauritian Cynomolgus Macaques. Infect Immun 85:
Rodrigues, Michelle A (2017) Female Spider Monkeys (Ateles geoffroyi) Cope with Anthropogenic Disturbance Through Fission-Fusion Dynamics. Int J Primatol 38:838-855
Buechler, Connor R; Bailey, Adam L; Lauck, Michael et al. (2017) Genome Sequence of a Novel Kunsagivirus (Picornaviridae: Kunsagivirus) from a Wild Baboon (Papio cynocephalus). Genome Announc 5:
Wu, Hong; Whritenour, Jessica; Sanford, Jonathan C et al. (2017) Identification of MHC Haplotypes Associated with Drug-induced Hypersensitivity Reactions in Cynomolgus Monkeys. Toxicol Pathol 45:127-133
Shackman, A J; Fox, A S; Oler, J A et al. (2017) Heightened extended amygdala metabolism following threat characterizes the early phenotypic risk to develop anxiety-related psychopathology. Mol Psychiatry 22:724-732
Kalin, Ned H (2017) Mechanisms underlying the early risk to develop anxiety and depression: A translational approach. Eur Neuropsychopharmacol 27:543-553

Showing the most recent 10 out of 528 publications